U.S FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press/Media

Period2 Mar 2022

Media coverage

1

Media coverage

  • TitleU.S FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
    Media name/outletImpact Financial News
    Country/TerritoryUnited Kingdom
    Date2/03/22
    PersonsSundar Jagannath
View all 1
View less